ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P ASX 200
7,683.00
-0.01%
S&P ASX All Technology
3,008.10
0.02%
Brent Oil
87.315
-0.29%
US Dollar vs AUD
1.53856
-0.17%
Bitcoin
64,413.12
-3.01%
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Arvinas Inc (ARVN)

  7. Arvinas Inc (ARVN) News

ARVN Arvinas Inc

32.81
-1.19 (-3.50%)
Last Updated: 05:19:24
Delayed by 15 minutes
Share Name Share Symbol Market Stock Type
Arvinas Inc ARVN NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
Upgrade Icon
-1.19 -3.50% 32.81 05:19:24
Open Price Low Price High Price Close Price Previous Close
33.82 32.61 33.90 34.00
more quote information »

Recent News

Date Time Source Heading
11/4/202421:00GLOBEArvinas Enters into a Transaction with Novartis, including a..
19/3/202407:40GLOBEArvinas Appoints Noah Berkowitz, M.D., Ph.D., as Chief..
04/3/202423:00GLOBEArvinas to Participate in Upcoming Investor Conferences
28/2/202410:35EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/2/202410:34EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/2/202410:33EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/2/202410:33EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/2/202408:46EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
27/2/202423:02EDGAR2Form 8-K - Current report
27/2/202423:00GLOBEArvinas Reports Fourth Quarter and Full Year 2023 Financial..
21/2/202408:06EDGAR2Form 8-K - Current report
21/2/202408:05GLOBEArvinas Announces Chief Financial Officer Transition
20/2/202423:00GLOBEArvinas Announces First-in-Human Dosing of ARV-102, an..
15/2/202400:00GLOBECarrick Therapeutics Announces First Patient Dosed in Phase..
14/2/202412:14EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
06/2/202422:45GLOBEArvinas and Pfizer’s Vepdegestrant (ARV-471) Receives FDA..
02/2/202408:30GLOBEArvinas to Present at 6th Annual Guggenheim Biotechnology..
17/1/202409:01GLOBEArvinas Appoints Jared Freedberg as General Counsel
17/1/202408:03EDGAR2Form S-8 - Securities to be offered to employees in employee..
09/1/202408:39EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/1/202423:45EDGAR2Form 8-K - Current report
09/12/202301:16EDGAR2Form S-3ASR - Automatic shelf registration statement of..
06/12/202323:01EDGAR2Form 8-K - Current report
06/12/202314:52GLOBEArvinas to Host Conference Call and Webcast to Discuss..
06/12/202305:33GLOBEArvinas and Pfizer Announce Interim Data from Phase 1b Trial..
29/11/202309:05GLOBEArvinas and Pfizer Announce Updated Vepdegestrant (ARV-471)..
27/11/202323:11EDGAR2Form 8-K - Current report
27/11/202323:00GLOBEArvinas Announces Oversubscribed $350 Million Private..
08/11/202309:24EDGAR2Form S-3ASR - Automatic shelf registration statement of..
08/11/202308:27EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/11/202323:03EDGAR2Form 8-K - Current report
07/11/202323:00GLOBEArvinas Reports Third Quarter 2023 Financial Results and..
02/11/202322:00GLOBEArvinas to Participate in Upcoming Investor Conferences
23/10/202323:30EDGAR2Form 8-K - Current report
22/10/202322:00GLOBEPotential of Arvinas’ PROTAC® AR Degraders Reinforced by..
18/10/202322:00GLOBEArvinas Gives Back to Local Greater New Haven Community in..
16/10/202309:07GLOBEArvinas Announces Upcoming Bavdegalutamide Poster..
16/10/202309:05GLOBEArvinas and Pfizer Announce Upcoming Vepdegestrant (ARV-471)..
01/9/202321:00GLOBEArvinas to Participate in Upcoming Investor Conferences
15/8/202307:27EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/8/202306:09EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/8/202321:03EDGAR2Form 8-K - Current report
08/8/202321:00GLOBEArvinas Reports Second Quarter 2023 Financial Results and..
01/8/202306:30GLOBEArvinas and Pfizer Awarded Innovation Passport Designation..
06/7/202323:00GLOBECarrick Therapeutics Announces Clinical Trial Collaboration..
16/6/202306:30GLOBEArvinas Announces Changes to its Board of Directors
08/6/202321:00GLOBEArvinas Announces Interim Data from the ARV-766 Phase 1/2..
05/6/202321:00GLOBEArvinas to Participate in Upcoming Investor Conferences
08/5/202321:00GLOBEArvinas and Pfizer Announce Upcoming Vepdegestrant (ARV-471)..
05/5/202321:00GLOBEArvinas Reports First Quarter 2023 Financial Results and..

Your Recent History

NASDAQ
ARVN
Arvinas
Delayed Upgrade Clock
ADVFN Logo

Australia
Company
Business
Popular
Get The App

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved